LYON, France & NEW YORK--(BUSINESS WIRE)--The Medicrea Group (Paris: ALMED) (Alternext Paris: FR0004178572 - ALMED), pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, announced 2016 half-year results to June 30, approved by the Board of Directors on September 19, 2016.
